European researchers have been tinkering with a protein that is naturally produced in the human body. Utilizing this protein to create a vaccine they hope to spur T cell activity that ceases inflammation and also play a role fighting Alzheimer’s, Parkinson’s, RA, AA, MS, type II diabetes and cancers.
The makers of the injectable Copaxone would like you to stay with their tratment for multiple sclerosis rather than switch to Gilenya the newly approved pill. Here is a take from a Copaxone user who recieved PR material from Teva that attempts to persuade him to stick with his present therapy.
I always used to wonder why northern latitudes suffered the greatest incidence of multiple sclerosis cases. Then I saw some research that suggested cigarette smoking could play a role. This made me wonder about the geographical anomalies still and then a thought struck, could it be component of the smoke itself, one that could be present in others smokes such as wood being burned in colder northern climates to heat our dwellings?
I am not sure if the environmental toxin “acrolein” is a component of any wood smoke but it is present in tobacco smoke and automobile exhaust. It is being studied for it’s possible role in the cause of multiple sclerosis.
Tongues are being stimulated and exercise is being practiced in this treatment regimen that is being developed to improve the gait, balance, posture, and limb control for persons with these neurological deficits due to illness, stroke or injury.
If MS patients were rats they could have been cured long ago.
A lot of treatment strategies have been successful for lab rodents only to fizzle in human application. One of the newest of these discoveries focuses on the injection of an anti-inflammatory medication that indicates a potential disease reversal in lab animals that have been paralyzed by the experimental disease meant to simulate multiple sclerosis in humans.
PV-267, a molecule thought to block the autoimmune response responsible for myelin destruction in persons with multiple sclerosis, gets a big boost from Fast Forward.
New details have come to light in the case of a Canadian multiple sclerosis patient that died because of complications following a CCVSI procedure that supposedly did not adhere to the strict Liberation Procedure’s protocols.
Some comments and observations from the 2010 ECTRIMS meeting in Sweden.
Proteins, Peptides Patch Poses Promise
Injecting and oral administration of myelin peptides have not garnered the positive results that had been hoped for, however Polish researchers have higher hopes for the skin patch used in a small double blind study. The results have them eager to expand and further investigate.